GLP-1 Pill Weight Loss Calculator

ATTAIN-1 ran 72 weeks with an average baseline of about 228 lb; OASIS-4 ran 64 weeks averaging about 235 lb. Similar populations, adults with obesity or overweight with a weight-related condition and without diabetes, but not the same trial, so read the table as two published results in one place.

The responder spread favors the tablet too: 27.9% of OASIS-4 participants lost at least 20% on the Wegovy pill, against 18.4% on Foundayo 17.2 mg in ATTAIN-1, and 76.3% versus 71.5% cleared 5%. One honesty note that cuts the other way: ATTAIN-1 publishes no intermediate timepoints at all, so Foundayo's monthly values above are the most loosely anchored on this site, and OASIS-4 was a small trial of 307 people against SURMOUNT-scale studies of thousands.

On paper the two pills are separated by about 2.5 percentage points. In practice the bigger separation may be the routine, because a pill only works at the rate you actually take it, 365 times a year.

The Wegovy tablet's label is strict: take it in the morning on an empty stomach with up to 4 oz of water, nothing else, then wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. If your mornings are chaotic, that rule is a real constraint, and it is the same constraint Rybelsus users already know.

Foundayo's label is one line: once daily, with or without food. No water limit, no wait. The trade-off shows up in the climb instead: Foundayo steps through 0.8, 2.5, and 5.5 mg at 30-day intervals, so the earliest anyone reaches the top 17.2 mg dose is around week 21. The Wegovy tablet escalates through 1.5, 4, and 9 mg and reaches its full 25 mg dose around week 13.

A daily pill also changes what is worth tracking: adherence over a run of days, not a weekly dose day. GlucoPal is a free iPhone app that tracks daily GLP-1 pills alongside weight, meals, and side effects, with a doctor-ready export.

On published averages, not quite. The pills sit at 11.1% to 13.6%, while the injections run from 14.9% on Wegovy 2.4 mg through 18.8% on Wegovy HD 7.2 mg to 20.9% on Zepbound or Mounjaro 15 mg. The Wegovy tablet lands within about a point of the 2.4 mg injection, which is the most meaningful comparison here since they are the same molecule, and the OASIS-4 paper positioned it as comparable to the injectable.

These are all separate trials, so the ordering is indicative rather than exact. The one true head-to-head in this space, SURMOUNT-5, compared the two injections, not a pill against an injection.

And the average is not the whole decision. A pill you take every day beats an injection you avoid, skip, or quit. If needles, refrigeration, or pen shortages are the reason a weekly injectable has not worked for you, the gap between 13.6% and 14.9% is a much smaller price than the gap between taking a medication and not taking one.

It is a reference point, not a forecast. The trial endpoints and responder percentages are verified published numbers from the FDA labels, using the conservative intention-to-treat estimands rather than the adherence-based ones quoted in press coverage. Everything between the endpoints is estimated, because neither trial publishes week-by-week numbers, and both pills are new enough that there is far less real-world follow-up behind them than behind the injectables.

Trial participants took the medication alongside a reduced-calorie diet and increased activity, individual results varied widely in both directions, and the trial populations may not match your situation. This page is educational information, not medical advice; the choice between these medications is a conversation for you and your prescriber.